Foundayo is Eli Lilly's brand name for orforglipron, the first small-molecule GLP-1 pill approved for obesity. The FDA cleared it in early April 2026; the IQVIA launch tracker has stepped up from 3,707 prescriptions in Week 2 to 5,612 in Week 3 to 7,335 in Week 4 (the week ending May 1, per Citi's May 8 client note). Citi flagged that the IQVIA data captures retail and partial telehealth, likely understating Lilly Direct and the 12+ telehealth firms that account for roughly 35% of launch volume — Lilly executives have cited 20,000 patients now on the drug. Citi modeled $146M in Q2 and $1.6B for full-year 2026. On the April 30 Q1 call, Lilly disclosed more than 8,000 prescribers (one-third writing an oral GLP-1 for the first time) and 80% of patients new to the GLP-1 class — with commercial access confirmed at two of the three largest US PBMs effective mid-May.
The ACHIEVE-3 obesity Phase 3 gave Foundayo HbA1c superiority versus oral semaglutide in type-2 diabetes, but indirect comparisons published just after launch suggested oral Wegovy may produce greater weight loss with fewer GI discontinuations. Managed Healthcare Executive's head-to-head writeup framed the choice as HbA1c lead versus weight-loss lead. On May 4, an FAERS hepatic-failure case in a 56-year-old male — logged April 30 — surfaced publicly. LLY fell 3% premarket before recovering as Lilly released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program. RBC Capital framed the case as 'baseline noise' and pointed to comparable hepatic-failure tallies for Mounjaro (30), Ozempic (33), Wegovy (15), and Zepbound (2).
Stories here cover prescription volumes, payer coverage, head-to-head comparisons with oral Wegovy, and side-effect signals from FAERS. See #orforglipron for the underlying molecule and #oral-glp-1 for class context.
IQVIA's weekly prescription tracker for Foundayo (orforglipron) hit approximately 17,000 prescriptions for the week ending May 15, 2026, per Citi's Friday client note — Lilly's first above-15,000 weekly print since the April 6 launch. The week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5), and ~17,000 in the new print. Novo Nordisk's Wegovy pill recorded roughly 142,000 prescriptions in the same week — the trajectory gap is narrowing as Foundayo's PBM coverage activates at the largest US plans but still remains 8.3x the Foundayo volume. Citi maintains $146M Foundayo Q2 revenue and $1.6B 2026 full-year estimates; the IQVIA print supports the trajectory. Lilly's late-May TV-advertising launch may amplify the next leg of Foundayo growth heading into mid-June.
Novo Nordisk's Executive Vice President for International Operations Emil Kongshøj Larsen told CNBC May 18 the company is preparing to go 'all in' on launching its Wegovy pill outside the US, with UK, Germany, and Denmark at the front of the international queue. The company disclosed cumulative US Wegovy pill prescriptions have crossed 2 million in the 18 weeks since the January 5 launch — roughly double the >1M figure CEO Maziar Doustdar shared on May 14. Larsen's quote: 'When we launch, we'll go all in.' The international expansion lands as Novo's full-year 2026 guidance still calls for revenue and profit declines between 4% and 12%, but the company hiked guidance slightly last week after Q1 oral semaglutide sales beat expectations. The international Wegovy pill timing matters for Lilly's Foundayo (orforglipron), which had its US PBM coverage activate mid-May but has no near-term international launch date.
The CNBC May 18 piece surfaced explicit company-supported positioning that Foundayo (orforglipron) and oral Wegovy are targeting different patient segments rather than competing head-to-head. Novo's framing for Wegovy pill is 'injectable-like efficacy' in oral form, with the Phase 3 OASIS-MAINTAIN data anchoring approximately 15% mean weight loss. Lilly's framing for Foundayo positions it as more of a 'starter' GLP-1 — lower weight-loss ceiling (around 11.2% in ATTAIN-1) but no food-or-water dosing restrictions and a non-peptide small-molecule manufacturing path that supports a lower long-term price. Both companies say the pills are expanding the market rather than significantly cannibalizing demand for the injectables — a different framing than the 'oral-disrupts-injectable' narrative that dominated 2025 coverage. The market-expansion hypothesis will be testable as ADA 2026 (June 5-8) and Q2 2026 earnings prints land.
Fierce Pharma's Oral GLP-1 Tracker reported the first weekly decline in Wegovy pill prescriptions since the January 5, 2026 launch: scripts dropped from ~143,000 to ~137,000 in the week ending May 8. Total Wegovy (injectable + pill) scripts climbed 1.3% w/w to ~446,000, taking obesity GLP-1 market share to 40.5%. Eli Lilly's Foundayo posted Week 5 IQVIA prescriptions of 10,248, up 40% w/w from Week 4's 7,335 — the steepest weekly growth in the launch series, attributed to mid-May commercial access activation at two of the three largest US PBMs. The cumulative US Wegovy pill user count crossed 1 million per Novo CEO Doustdar's May 14 commentary; the Wegovy injectable continues to be the largest US GLP-1 single-product line. The Wegovy pill plateau and Foundayo acceleration narrow the trajectory gap that has defined the oral-GLP-1 race since April.
Eli Lilly executives confirmed on the April 30 Q1 call that a full direct-to-consumer TV advertising campaign for Foundayo (orforglipron) launches in late May 2026, coinciding with the mid-May commercial access activation at two of the three largest US pharmacy benefit managers. The campaign emphasizes Foundayo's only-oral-GLP-1-without-food-or-water-restrictions positioning vs Novo's Wegovy pill, which requires fasting administration. Lilly previously held back consumer advertising through the first six weeks of launch to let PBM coverage scale before driving consumer prescription demand. Citi's May 8 IQVIA note flagged the upcoming campaign and PBM expansion as the catalysts for the Week 5+ trajectory acceleration that landed in the May 8 IQVIA print (10,248 scripts, +40% w/w).
Citi's Friday May 15 client note reported Foundayo (orforglipron) hit 10,248 US prescriptions in the week ending May 8 per IQVIA — the first 40% week-over-week jump in the launch series. Week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5). The acceleration aligns with mid-May commercial access activation at two of the three largest US PBMs that Lilly flagged on the April 30 Q1 call. Citi maintained $146M Q2 revenue and $1.6B full-year 2026 estimates. The Wegovy pill remains ahead — Novo CEO Doustdar's May 14 commentary confirmed >1M cumulative US users since the January 5 launch — but the gap is narrowing as Foundayo's PBM coverage comes online and telehealth volume (~35% of total per Lilly executives, not captured in retail-only IQVIA data) layers on top.
Eli Lilly executives' Q1 commentary clarified the Foundayo launch-channel mix: roughly 45% via LillyDirect (the company's direct-to-patient pharmacy), 35% via telehealth platforms not captured in retail-only IQVIA data, and 20% via traditional retail pharmacy fills. The split helps explain the apparent gap between Citi's IQVIA-reported 10,248 Week 5 prescriptions and the 20,000+ patient count Lilly disclosed on the April 30 Q1 call. The pattern suggests Foundayo is being adopted preferentially through digitally-enabled care channels — Hims & Hers, LifeMD, JoinFound, and other telehealth platforms with weight-management Rx infrastructure — rather than primary-care prescribing. The mix is structurally similar to the Wegovy pill launch but with a higher telehealth share. The implication for the next 90 days: PBM coverage expansion (mid-May) and brand-name TV advertising (launching late May per the Q1 commentary) will drive most of the next leg of growth.
The next Foundayo IQVIA prescription tracker update is expected from Citi mid-week May 18-20, covering the week ending May 8. Week 4 hit 7,335 prescriptions per the May 8 Citi note with Lilly executives citing 20,000 total patients (~35% via telehealth not captured in the retail-only IQVIA data). Citi's projected $146M Q2 revenue and $1.6B full-year 2026 estimate continue to anchor the analyst consensus. Lilly executives have asked analysts for 8-12 weeks of data before reading commercial trajectory through pharmacy-fill noise; the Week 5 reading is the first post-PBM-coverage-expansion data point as the two largest US PBMs went live with Foundayo coverage mid-May. The Wegovy pill remains roughly 60-70x ahead on weekly volume (>440K in the week ending May 1 per Novo's Q1 commentary).
Eli Lilly published SURMOUNT-MAINTAIN in The Lancet and ATTAIN-MAINTAIN in Nature Medicine on May 12, with concurrent presentation at ECO 2026 in Istanbul. SURMOUNT-MAINTAIN tested lower-dose Zepbound (tirzepatide 5 mg) vs maximum tolerated dose: at week 112, MTD preserved all weight loss while the 5 mg arm lost only 5.6 kg additional. ATTAIN-MAINTAIN tested Foundayo (orforglipron) as a switch from injectable GLP-1s in SURMOUNT-5 participants: orforglipron preserved 79.3% of injectable-phase weight loss vs 37.6% on placebo at week 52; Wegovy MTD switchers regained only 0.9 kg, Zepbound MTD switchers regained 5.0 kg. The dual readout reframes the maintenance-versus-discontinuation conversation: dose-tapering and oral-switching strategies now have Phase 3 evidence behind them, validating the long-term-treatment chronic-disease framing.
An ORION indirect treatment comparison presented at ECO 2026 on May 13 framed the head-to-head competition between Novo's Wegovy pill (oral semaglutide 25 mg) and Lilly's Foundayo (orforglipron 36 mg). The Wegovy pill delivered statistically significant greater mean weight loss than orforglipron, with patients on orforglipron showing approximately 14x higher odds of discontinuing treatment due to gastrointestinal side effects. The May 13 framing complements Novo's Q1 print disclosure that Wegovy holds 65% of all new US GLP-1 prescriptions; CEO Mike Doustdar's CNBC commentary called the moment a 'turnaround situation' for the Danish company. The ORION ITC matters as a prescriber-decision tool given the two compounds are now the only two FDA-approved oral GLP-1s for chronic weight management.
Eli Lilly's Foundayo (orforglipron) reached UAE pharmacies on May 12 in Abu Dhabi, expanding from the April Dubai launch. The Emirates Drug Establishment first approved Foundayo on April 3, making the UAE the second country globally to register the once-daily oral GLP-1 pill. Pricing runs from AED 773/month for the 0.8 mg starter dose to AED 1,599/month for the 17.2 mg highest dose. Abu Dhabi has folded Foundayo into the emirate's broader weight-loss program, signaling government coverage rather than purely self-pay. The launch is one of the first international rollouts since FDA approval April 1; Lilly executives have framed UAE prescribing patterns and patient adherence as an early read on geriatric and Middle East regional patient response.
Eli Lilly on May 6 cut the ribbon on Lilly Lebanon Advanced Therapies — the company's first dedicated genetic medicine manufacturing facility — and committed an additional $4.5B across two more LEAP Research and Innovation District sites in Lebanon, Indiana. The new investment supports planned production of Foundayo (orforglipron), Lilly's only FDA-approved GLP-1 pill that does not require fasting or water restrictions, and retatrutide, the triple GLP-1/GIP/glucagon agonist in seven Phase 3 trials. Total Indiana capital commitments since 2020 now exceed $21B, with the LEAP District alone totaling $18B since 2022 — the largest capital project in Indiana history. The buildout will add more than 1,000 jobs by 2027 and gives Lilly a domestic Foundayo + retatrutide supply chain independent of peptide-CDMO bottlenecks.
A post-hoc subgroup analysis of Eli Lilly's orforglipron (Foundayo) in adults aged 65 and older, drawn from the ATTAIN-1 and ATTAIN-2 Phase 3 programs, will be presented at ECO 2026 in Istanbul May 12-15. The analysis pools 616 randomized participants (613 treated) — 118 on 6 mg, 135 on 12 mg, 146 on 36 mg orforglipron, and 214 placebo — across patients with and without type 2 diabetes. The geriatric data set addresses a long-standing clinical gap: incretin trials have systematically underenrolled adults over 65, the population most affected by obesity-related comorbidities and the most likely to face polypharmacy-related GI tolerability concerns. Lead author Dr. Deborah Horn (UTHealth Houston McGovern Medical School). The presentation is among the ECO 2026 abstracts that will shape geriatric prescribing patterns for the first FDA-approved GLP-1 pill that does not require fasting or water restrictions.
In its fourth commercial week (April 27–May 1), Eli Lilly's Foundayo (orforglipron) recorded 7,335 prescriptions per IQVIA, Citi told clients May 8, calling the early launch 'off to a solid start' and modeling $146M in Q2 revenue and $1.6B for full-year 2026. Citi flagged that IQVIA captures retail and partial telehealth data but likely understates Lilly Direct and the 12+ telehealth firms representing roughly 35% of launch volume; Lilly executives have cited 20,000 patients now on Foundayo. For comparison, Citi's same note pegged Wegovy pill at 440,410 prescriptions in the week ending May 1, with oral semaglutide accounting for 33% of all Novo obesity referrals.
NPR ran a consumer-facing explainer May 6 of the Medicare GLP-1 Bridge demonstration that begins July 1, 2026 and runs through December 31, 2027. Eligible Medicare Part D beneficiaries can access Wegovy, Foundayo, and the Zepbound KwikPen formulation for a $50/month copay through the Bridge after meeting prior-authorization criteria. The piece consolidates a regulatory thread that has been jagged in mainstream coverage — the BALANCE pilot's collapse in late April when CVS pulled out, the Trump-administration extension of the Bridge to 2027, and the May 2026 confirmation that state Medicaid agencies can opt in. NPR's translation arrives in the same window as Novo's May 6 Q1 print and the Hims & Hers May 11 print, both of which are partly leveraged on Bridge eligibility expanding the addressable patient base.
An FDA Adverse Event Reporting System (FAERS) entry logged April 30 surfaced publicly May 4, documenting hepatic failure in a 56-year-old male patient on Foundayo (orforglipron). The case was marked for expedited review and could have occurred at or before April 15 — Foundayo only launched April 9. There have been 34 total Foundayo FAERS reports so far, with two considered serious. LLY traded down nearly 3% premarket — hitting roughly $936 — before recovering on Lilly's response. Foundayo's label carries a warning that the medication is 'not recommended for use in patients with severe hepatic impairment' (orforglipron is primarily hepatically metabolized), but mild and moderate liver impairment is allowed at standard dose.
Eli Lilly's Global Patient Safety team responded to the FDA's request for updated Foundayo safety information on May 4, concluding the FAERS event was 'not reasonably related to Foundayo.' The company pointed to the 11,000-participant ACHIEVE and ATTAIN program — followed for up to two years — where the liver safety profile of Foundayo was similar to placebo and active comparator medicines, with no cases of drug-induced liver injury observed and no hepatic safety signal detected. ACHIEVE-4 specifically included a thorough drug-induced liver injury (DILI) analysis with no hepatic signals, consistent with the 57% lower all-cause death rate (HR 0.43) seen versus insulin glargine in that arm.
RBC Capital reiterated its Outperform rating on Eli Lilly May 4 with the framing 'baseline noise, not a mechanistic safety signal,' and put the single Foundayo case in context against the broader GLP-1 class hepatic failure tally: Mounjaro 30 cases, Zepbound 2, Ozempic 33, Wegovy 15. Other Street analysts followed similar reasoning. The defense rests on the 11,000-patient clinical program and the absence of any DILI signal across two years of follow-up. The framing matters because the launch trajectory for Foundayo had already been challenged by IQVIA tracker data showing the Wegovy pill running roughly 20× ahead in retail prescriptions; a sustained safety overhang would compound the commercial pressure.